Aurion Biotech

Aurion Biotech is a clinical-stage biotech company whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. Its first product candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care.

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results

In both trials, CSF-1 met its primary and key secondary endpoints on Day 8, achieving statistically significant 3-line or more gain in distance-corrected near visual acuity (DCNVA), and no loss of 1-line or more in distance visual acuity. Pooled across the two studies, 40% and 50% of participants demonstrated these gains 1-hour post-dose 1 and 1-hour post-dose 2 respectively (P<0.0001). CSF-1 also achieved statistically significant 3-line improvement at all measured time points on Days 1 and 15. On Day 15, participants achieved statistically significant 3-line or more improvement in DCNVA as early as 20 minutes and up to 8 hours post-dose 1. In addition, CSF-1 demonstrated an excellent tolerability and safety profile, with comparable redness and comfort versus vehicle, validating the preservative-free presentation and proprietary formulation of CSF-1. The most common treatment-related adverse events of headache and instillation sight pain occurred in only 6.8% and 5.8% of participants, respectively. Of all CSF-1 participants, only 2.6% reported moderate treatment-related adverse events. All other adverse events were mild.

Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures

Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has secured a $120 million financing with top-tier biotech and ophthalmology investors. The financing was led by Deerfield Management, and included existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform supported by KKR, and Visionary Ventures, a leading ophthalmology-focused venture fund creating value with better insight. Alcon also participated in the financing. Funds will be disbursed to the Company based on the achievement of key clinical and operational milestones.

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

Visionary Ventures led a $45MM round into its 12th portfolio company, Sydnexis. Sydnexis is a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi. The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.


Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia. Myopia is a growing public health challenge worldwide that’s expected to affect 5 billion people by the year 2050.

RxSight, Inc. Announces Closing of Initial Public Offering

RxSight, Inc., an ophthalmic medical device company, today announced the closing of its initial public offering raising $132MM. RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens.

Orasis Appoints Industry Veteran, Paul Smith, as President and Chief Operating Officer to Lead the Next Phase of Growth

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.

Visionary Ventures Closes Fund II with $114MM in Committed Capital

Aliso Viejo, California, March 23, 2021 – Visionary Ventures today announced the closing of Visionary Venture Fund II with $114MM in committed capital. The Fund, which was strongly supported by existing and new investors, continues the firm’s strategy of partnering with Ophthalmology and Optometry Key Opinion Leader (KOL) limited partners to invest in ophthalmic pharmaceuticals and medical devices. Fund II enjoys investment and input from over 80 KOL experts spanning the front and back of the eye.